Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen , Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen , Richard S. Finn , Peter R. Galle , Josep M. Llovet , Eric Assénat , Giovanni Brandi , Marc Pracht , Ho Yeong Lim , Kun‐Ming Rau , Kenta Motomura , Izumi Ohno , Philippe Merle , Bruno Daniele , Dong Bok Shin , Guido Gerken , Christophe Borg , Jean‐Baptiste Hiriart , Takuji Okusaka , Manabu Morimoto , Yanzhi Hsu , P. Abada , Masatoshi Kudo
2019 The Lancet Oncology 1,593 citations

Keywords

RamucirumabMedicineSorafenibHepatocellular carcinomaInternal medicinePlaceboClinical endpointCirrhosisGastroenterologyLiver cancerRandomized controlled trialCarcinomaCancerOncologySurgeryPathology

Affiliated Institutions

Related Publications

Publication Info

Year
2019
Type
article
Volume
20
Issue
2
Pages
282-296
Citations
1593
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1593
OpenAlex

Cite This

Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen et al. (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology , 20 (2) , 282-296. https://doi.org/10.1016/s1470-2045(18)30937-9

Identifiers

DOI
10.1016/s1470-2045(18)30937-9